Search
Amgen Inc
AMGNAdd to Watchlist
344.735USD
+7.135+2.11%
Close 06/22, 16:00（ET）Quotes delayed by 15 min
185.74BMarket Cap
23.80P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.11%
5 Days
-1.65%
1 Month
+1.60%
6 Months
+4.03%
Year to Date
+5.32%
1 Year
+19.15%
Key Figures
337.650Open
345.110High
2.52MVolume
23.80P/E TTM
14.69P/E Dynamic
9.800Dividend TTM
0.47%Turnover Ratio
337.600Prev. Close
337.600Low
710.36MTurnover
45.41P/E Static
21.45P/B
2.84%Div Yield TTM
8.58%ROA
391.29052wk High
0.57Volume Ratio
4.09BNet Profit
538.80MShares
14.4856EPS TTM
0.42Beta
101.32%ROE
267.83052wk Low
2.22%Amplitude
71.03%Gross Margin
185.74BMarket Cap
0.03Reward/Risk
1.54%Risk Rate
TradingKey Stock Score of Amgen Inc
Currency: USD Updated: 2026-06-22Key Insights
Amgen Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 28 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 359.56.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amgen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
47°C
Very Low
Very High
Negative
Amgen Inc Highlights
StrengthsRisks
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 30.37% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.
Fairly Valued
The company’s latest PE is 23.80, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 460.83M shares, increasing 0.49% quarter-over-quarter.
Held by Bill Smead
Star Investor Bill Smead holds 725.23K shares of this stock.
Analyst Rating
Based on
38
analysts
Hold
Current Rating
359.556
Target Price
+6.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amgen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amgen Inc Info
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Ticker SymbolAMGN
CompanyAmgen Inc
CEOBradway (Robert A)
Websitehttps://www.amgen.com/
Related Instruments
+0.50%
+1.28%
+0.83%
+6.26%
+1.27%
+1.42%
+0.90%
+6.27%
-0.54%
+3.36%
+1.30%
+0.14%
-1.38%
-0.73%
0.00%
+0.41%
+2.98%
+0.40%
-1.09%Popular Instruments
73.665
-0.324 (-0.44%)
297.230
-0.780 (-0.26%)
208.780
-1.910 (-0.91%)
4136.180
-54.070 (-1.29%)
732.810
-13.420 (-1.80%)
2273.370
+88.620 (+4.06%)
1213.000
+79.010 (+6.97%)
349.710
-18.320 (-4.98%)
63938.430
-465.370 (-0.72%)
404.920
+4.430 (+1.11%)
FAQs
What is the current price of Amgen Inc (AMGN)?
The current price of Amgen Inc (AMGN) is 344.74.
What is the symbol of Amgen Inc?
The ticker symbol of Amgen Inc is AMGN.
What is the 52-week high of Amgen Inc?
The 52-week high of Amgen Inc is 391.29.
What is the 52-week low of Amgen Inc?
The 52-week low of Amgen Inc is 267.83.
What is the market capitalization of Amgen Inc?
The market capitalization of Amgen Inc is 185.74B.
Is Amgen Inc (AMGN) currently rated as Buy, Hold, or Sell?
According to analysts, Amgen Inc (AMGN) has an overall rating of signal_hold, with a price target of 359.56.
What is the Earnings Per Share (EPS TTM) of Amgen Inc (AMGN)?
The Earnings Per Share (EPS TTM) of Amgen Inc (AMGN) is 14.33.
